Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 110

1.
2.

Risedronate and ergocalciferol prevent hip fracture in elderly men with Parkinson disease.

Sato Y, Honda Y, Iwamoto J.

Neurology. 2007 Mar 20;68(12):911-5.

PMID:
17372126
3.

Once-weekly risedronate for prevention of hip fracture in women with Parkinson's disease: a randomised controlled trial.

Sato Y, Iwamoto J, Honda Y.

J Neurol Neurosurg Psychiatry. 2011 Dec;82(12):1390-3. doi: 10.1136/jnnp.2011.244574. Epub 2011 Aug 8.

PMID:
21825080
4.
6.

Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Fosamax International Trial Study Group.

Pols HA, Felsenberg D, Hanley DA, Stepán J, Muñoz-Torres M, Wilkin TJ, Qin-sheng G, Galich AM, Vandormael K, Yates AJ, Stych B.

Osteoporos Int. 1999;9(5):461-8.

PMID:
10550467
7.

Alendronate increases bone mass and reduces bone markers in postmenopausal African-American women.

Bell NH, Bilezikian JP, Bone HG 3rd, Kaur A, Maragoto A, Santora AC; MK-063 Study Group.

J Clin Endocrinol Metab. 2002 Jun;87(6):2792-7.

PMID:
12050252
8.

Menatetrenone and vitamin D2 with calcium supplements prevent nonvertebral fracture in elderly women with Alzheimer's disease.

Sato Y, Kanoko T, Satoh K, Iwamoto J.

Bone. 2005 Jan;36(1):61-8. Epub 2004 Nov 24.

PMID:
15664003
9.

Effectiveness and safety of vitamin D in relation to bone health.

Cranney A, Horsley T, O'Donnell S, Weiler H, Puil L, Ooi D, Atkinson S, Ward L, Moher D, Hanley D, Fang M, Yazdi F, Garritty C, Sampson M, Barrowman N, Tsertsvadze A, Mamaladze V.

Evid Rep Technol Assess (Full Rep). 2007 Aug;(158):1-235. Review.

10.

Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group.

Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE.

Lancet. 1996 Dec 7;348(9041):1535-41.

PMID:
8950879
11.

Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension.

Ensrud KE, Barrett-Connor EL, Schwartz A, Santora AC, Bauer DC, Suryawanshi S, Feldstein A, Haskell WL, Hochberg MC, Torner JC, Lombardi A, Black DM; Fracture Intervention Trial Long-Term Extension Research Group.

J Bone Miner Res. 2004 Aug;19(8):1259-69. Epub 2004 Mar 29.

12.

Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis. Fracture Intervention Trial Research Group.

Hochberg MC, Ross PD, Black D, Cummings SR, Genant HK, Nevitt MC, Barrett-Connor E, Musliner T, Thompson D.

Arthritis Rheum. 1999 Jun;42(6):1246-54.

13.
14.

Vitamin D and vitamin D analogues for preventing fractures in post-menopausal women and older men.

Avenell A, Mak JC, O'Connell D.

Cochrane Database Syst Rev. 2014 Apr 14;(4):CD000227. doi: 10.1002/14651858.CD000227.pub4. Review.

PMID:
24729336
15.

Health-economic comparison of three recommended drugs for the treatment of osteoporosis.

Brecht JG, Kruse HP, Möhrke W, Oestreich A, Huppertz E.

Int J Clin Pharmacol Res. 2004;24(1):1-10.

PMID:
15575171
16.

Effect of low-dose alendronate treatment on bone mineral density and bone turnover markers in Chinese postmenopausal women with osteopenia and osteoporosis.

Li M, Zhang ZL, Liao EY, Chen DC, Liu J, Tao TZ, Wu W, Xia WB, Lu YJ, Sheng ZF, Lu CY, Meng GL, Xu L, Zhang WJ, Hu YY, Xu L.

Menopause. 2013 Jan;20(1):72-8. doi: 10.1097/gme.0b013e31825fe2e8.

PMID:
22968256
17.

Markers of bone resorption predict hip fracture in elderly women: the EPIDOS Prospective Study.

Garnero P, Hausherr E, Chapuy MC, Marcelli C, Grandjean H, Muller C, Cormier C, Bréart G, Meunier PJ, Delmas PD.

J Bone Miner Res. 1996 Oct;11(10):1531-8.

PMID:
8889854
18.

Effect of alendronate on the age-specific incidence of symptomatic osteoporotic fractures.

Hochberg MC, Thompson DE, Black DM, Quandt SA, Cauley J, Geusens P, Ross PD, Baran D; FIT Research Group.

J Bone Miner Res. 2005 Jun;20(6):971-6. Epub 2005 Jan 18.

19.

Increments in bone mineral density of the lumbar spine and hip and suppression of bone turnover are maintained after discontinuation of alendronate in postmenopausal women.

Stock JL, Bell NH, Chesnut CH 3rd, Ensrud KE, Genant HK, Harris ST, McClung MR, Singer FR, Yood RA, Pryor-Tillotson S, Wei L, Santora AC 2nd.

Am J Med. 1997 Oct;103(4):291-7.

PMID:
9382121
20.

Amelioration of osteoporosis by menatetrenone in elderly female Parkinson's disease patients with vitamin D deficiency.

Sato Y, Honda Y, Kaji M, Asoh T, Hosokawa K, Kondo I, Satoh K.

Bone. 2002 Jul;31(1):114-8. Erratum in: Bone. 2008 Jul;43(1):217.

PMID:
12110423

Supplemental Content

Support Center